8-K: Spyre Therapeutics Unveils Positive Phase 1 Results for Next-Generation TL1A Antibodies, Initiates Broad Phase 2 Clinical Program

Spyre Therapeutics announced positive interim Phase 1 results for its investigational anti-TL1A antibodies, SPY002 and SPY072, demonstrating favorable safety and prolonged half-life, and unveiled plans for extensive Phase 2 trials in inflammatory bowel disease and rheumatologic conditions.

Summary

• Positive interim Phase 1 results were announced for SPY002 and SPY072, two investigational extended half-life monoclonal antibodies targeting TL1A.
• Single doses of up to 1500 mg for both SPY002 and SPY072 were well tolerated, with no serious adverse events reported.
• SPY002 demonstrated an estimated half-life of approximately 75 days, which is more than 3-fold greater than first-generation anti-TL1A antibodies.
• The pharmacokinetic (PK) profile of both drugs supports potential for chronic dosing via a single subcutaneous injection on a quarterly or twice-annual basis.
• Both SPY002 and SPY072 achieved complete suppression of free TL1A to below the lower-limit of quantitation through 20 weeks of follow-up at the lowest dose tested (100 mg).
• The company initiated its SKYLINE-UC platform trial in May 2025 for ulcerative colitis, which will evaluate SPY001, SPY002, SPY003, and combinations thereof.
• Spyre unveiled its SKYWAY-RD basket trial for SPY072, targeting rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with initiation expected in Q3 2025.
• Spyre anticipates delivering 9 proof-of-concept readouts across its pipeline in 2026 and 2027.
• The company reported a cash runway extending into the second half of 2028, supported by $565 million in cash, cash equivalents, and marketable securities as of March 31, 2025.

Sentiment

Score: 9

Explanation: The document reports highly positive interim Phase 1 results for two key drug candidates, demonstrating superior pharmacokinetic profiles and favorable safety. It outlines an aggressive and well-funded Phase 2 development plan with multiple anticipated proof-of-concept readouts, targeting large market opportunities. The strategic approach to combination therapies and efficient trial designs further enhances the positive outlook.

Positives

• SPY002 and SPY072 demonstrated a favorable safety profile across all dose groups, with no serious adverse events or Grade 3/4 treatment-emergent adverse events (TEAEs) reported.
• The estimated half-life of SPY002 is approximately 75 days, which is more than 3-fold greater than first-generation anti-TL1A antibodies, supporting less frequent dosing.
• Pharmacokinetic data for both SPY002 and SPY072 support potential for chronic dosing via a single subcutaneous injection on a quarterly or twice-annual basis, enhancing patient convenience.
• Both SPY002 and SPY072 achieved complete suppression of free TL1A at the lowest dose (100 mg) through 20 weeks of follow-up, indicating strong and durable target engagement.
• No apparent impact of anti-drug antibodies (ADAs) was observed on pharmacokinetics or pharmacodynamics.
• The company has initiated the SKYLINE-UC platform trial for ulcerative colitis, an efficient design to evaluate multiple monotherapies and combinations under a single master protocol.
• The SKYWAY-RD basket trial for rheumatologic conditions (RA, PsA, axSpA) is planned, leveraging an efficient design for multiple indications with shared sites and specialty.
• Spyre anticipates 9 proof-of-concept readouts across its pipeline in 2026-2027, representing significant value inflection points.
• The company is well-funded with $565 million in cash as of March 31, 2025, providing a cash runway into the second half of 2028.
• Preclinical studies showed SPY002 and SPY072 had potency equivalent to or better than first-generation anti-TL1As.
• SPY072 demonstrated superior efficacy compared to etanercept (an anti-TNF drug) in a semi-preventative rat model of arthritis and comparable efficacy in a therapeutic model.

Negatives

• The most common treatment-emergent adverse events (TEAEs) for SPY002 were COVID-19 and for SPY072 were nausea; however, these were not greater than Grade 2 and did not lead to trial discontinuation.

Risks

• Final SPY002 and SPY072 Phase 1 trial data readouts may not be consistent with or may differ from the interim results reported.
• Regulatory authorities may disagree with the company's interpretation of data or planned clinical trials, including the SKYWAY-RD Phase 2 clinical trial design.
• Uncertainties and factors described under 'Risk Factors,' 'Risk Factor Summary,' and 'Note about Forward-Looking Statements' in Spyre's most recent Quarterly Report on Form 10-Q and other SEC filings.
• Potential impact of Trump Administration policies and changes in law on the business.
• General risks associated with companies operating in the biopharma industry, including the inherent uncertainties of drug development.

Future Outlook

Spyre Therapeutics anticipates significant progress in its clinical pipeline, with 9 proof-of-concept readouts expected in 2026 and 2027 across its SKYLINE-UC and SKYWAY-RD trials. The company aims to deliver best-in-class monotherapies and potentially first-in-class combinations with improved efficacy and convenience, including quarterly or twice-annual dosing, for inflammatory bowel disease and rheumatologic conditions. They project their current funding will support operations into the second half of 2028.

Management Comments

• "These interim results demonstrate clear benefits of our anti-TL1A approach versus first-generation molecules, underscoring the promise and potential of SPY002 and SPY072 as transformational therapies in immune-mediated diseases." Josh Friedman, M.D., Ph.D., SVP of Clinical Development.
• "We are excited to advance both programs into Phase 2, with the planned addition of SPY002 to our ongoing SKYLINE-UC trial and initiation of a novel basket trial, SKYWAY-RD, with SPY072." Josh Friedman, M.D., Ph.D., SVP of Clinical Development.
• "The SKYLINE-UC study will test optimized versions of the best monotherapies in IBD and combinations of those monotherapies, aiming to identify therapies that deliver a step change in efficacy and convenience compared to today's standard of care." Sheldon Sloan, MD, Chief Medical Officer.
• "Initiation of our Phase 2 SKYLINE-UC trial and planned initiation of our Phase 2 SKYWAY-RD trial marks a significant inflection point as we begin to explore the potential of our pipeline to deliver breakthroughs for patients with hard-to-treat inflammatory diseases." Cameron Turtle, DPhil, Chief Executive Officer.
• "With cash runway into the second half of 2028, we are well-funded to deliver 9 proof-of-concept readouts over the next two years in markets totaling >$60B of annual revenue. We believe our high-probability science and efficient development program provides the potential for exceptional stockholder value creation." Cameron Turtle, DPhil, Chief Executive Officer.

Industry Context

Spyre Therapeutics is positioning its anti-TL1A antibodies, SPY002 and SPY072, as next-generation therapies in the competitive inflammatory bowel disease (IBD) and rheumatologic disease markets. The reported prolonged half-life (estimated ~75 days for SPY002, over 3-fold greater than first-generation anti-TL1As) and potential for quarterly or twice-annual dosing aim to offer significant convenience advantages over existing therapies. The company's strategy of developing both monotherapies and rational combinations (e.g., anti-TL1A with anti-4b7 or anti-IL-23) seeks to achieve superior efficacy, potentially 'breaking the efficacy ceiling' compared to current standard-of-care biologics and even some bispecific approaches which have shown high immunogenicity.

Comparison to Industry Standards

• SPY002's estimated half-life of approximately 75 days is more than 3-fold greater than first-generation anti-TL1A antibodies.
• SPY002 and SPY072 demonstrated potency equivalent to or better than first-generation anti-TL1As in head-to-head preclinical studies.
• The pharmacokinetic profile of SPY002 and SPY072 supports potential for chronic dosing in a single subcutaneous injection on a quarterly or twice-annual basis, offering improved convenience compared to current standard of care IBD biologics.
• The company's combination therapies (SPY120, SPY130, SPY230) are designed to potentially break the efficacy ceiling, aiming for a step change in efficacy compared to today's standard of care.
• Co-administration of monoclonal antibodies (as planned by Spyre) can reduce immunogenicity, whereas some bispecific formats (e.g., JNJ-3539, JNJ-8104, AMG-966, MEDI-7352, RO7837195) have shown high immunogenicity rates (93-100%) and loss of drug exposure.
• SPY072 showed superior efficacy compared to etanercept (an anti-TNF drug) in a semi-preventative rat model of arthritis and comparable efficacy in a therapeutic model.

Stakeholder Impact

• Shareholders: Positive interim clinical data, efficient trial designs, and a strong cash runway into H2 2028 suggest potential for significant stockholder value creation. The company anticipates 9 proof-of-concept readouts, which are key value inflection points.
• Patients: The development of extended half-life antibodies (SPY002, SPY072) with potential for quarterly or twice-annual subcutaneous dosing offers improved convenience and potentially better adherence for patients with chronic inflammatory diseases like IBD, RA, PsA, and axSpA. The aim for 'step change in efficacy' could lead to better treatment outcomes.
• Healthcare Providers: The potential for less frequent dosing and improved efficacy could simplify treatment regimens and offer more effective options for managing complex immune-mediated diseases.

Next Steps

• Host a conference call and webcast on June 17, 2025, to discuss results and Phase 2 plans.
• Advance SPY002 into the SKYLINE-UC platform trial for ulcerative colitis.
• Initiate the SKYWAY-RD basket trial for SPY072 in RA, PsA, and axSpA in Q3 2025.
• Planned Phase 1 interim readout of SPY003 (anti-IL-23) in the second half of 2025.
• Read out open-label monotherapy data for SPY001, SPY002, SPY003 from SKYLINE-UC trial in 2026.
• Read out three placebo-controlled readouts for SPY072 in RA, PsA, and axSpA from SKYWAY-RD trial in 2026.
• Read out placebo-controlled data of monotherapies and combination therapies from SKYLINE-UC study in 2027.

Key Dates

Recommendation

Keywords

Spyre Therapeutics, SYRE, biotechnology, clinical-stage, monoclonal antibodies, TL1A, SPY002, SPY072, Phase 1 results, Phase 2 trials, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, IBD, immune-mediated diseases, drug development, pharmacokinetics, pharmacodynamics, extended half-life, SKYLINE-UC, SKYWAY-RD